Cargando…
Efficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring
AIMS/INTRODUCTION: The combination therapy of dipeptidyl‐peptidase (DPP)‐4 inhibitor and α‐glucosidase inhibitors (α‐GIs) is highly effective in suppressing postprandial hyperglycemia. The aim of the present study was to compare the effects of voglibose and miglitol on glucose fluctuation, when used...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley-Blackwell
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020235/ https://www.ncbi.nlm.nih.gov/pubmed/24843685 http://dx.doi.org/10.1111/jdi.12059 |
_version_ | 1782316035073900544 |
---|---|
author | Kurozumi, Akira Okada, Yosuke Mori, Hiroko Arao, Tadashi Tanaka, Yoshiya |
author_facet | Kurozumi, Akira Okada, Yosuke Mori, Hiroko Arao, Tadashi Tanaka, Yoshiya |
author_sort | Kurozumi, Akira |
collection | PubMed |
description | AIMS/INTRODUCTION: The combination therapy of dipeptidyl‐peptidase (DPP)‐4 inhibitor and α‐glucosidase inhibitors (α‐GIs) is highly effective in suppressing postprandial hyperglycemia. The aim of the present study was to compare the effects of voglibose and miglitol on glucose fluctuation, when used in combination with DPP‐4 inhibitor by using continuous glucose monitoring (CGM). MATERIALS AND METHODS: In a randomized cross‐over study, 16 patients with type 2 diabetes who presented with postprandial hyperglycemia despite alogliptin (25 mg) were treated with voglibose (0.9 mg) or miglitol (150 mg). We measured standard deviation (SD); mean amplitude of glycemic excursions (MAGE), and mean, minimum and maximum glucose measured by CGM during three phases (alogliptin monotherapy, dual therapy of alogliptin and voglibose, and dual therapy of alogliptin and miglitol). The primary outcome measure was SD between α‐GIs. RESULTS: SD was significantly improved by the addition of either voglibose (18.9 ± 10.1) or miglitol (19.6 ± 8.2) to alogliptin monotherapy (36.2 ± 8.7). MAGE improved significantly with the addition of either voglibose (57.5 ± 26.1, P < 0.01) or miglitol (64.6 ± 26.2, P < 0.01) to alogliptin monotherapy (101.5 ± 21.5). There was no significant difference in glucose fluctuation between α‐GIs. There were no differences between two groups in mean (132.6 ± 21.4 and 138.7 ± 25.4) and maximum (184.3 ± 48.7 and 191.9 ± 38.3). The minimum glucose under alogliptin plus voglibose (94.9 ± 20.2) was significantly lower than that under alogliptin and miglitol (105.3 ± 21.0). CONCLUSIONS: Glucose fluctuation was improved by the addition of voglibose or miglitol to alogliptin. Glucose fluctuations and postprandial hyperglycemia were similar between α‐GIs. This trial was registered with the University Hospital Medical Information Network (no. UMIN R000010028). |
format | Online Article Text |
id | pubmed-4020235 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Wiley-Blackwell |
record_format | MEDLINE/PubMed |
spelling | pubmed-40202352014-05-19 Efficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring Kurozumi, Akira Okada, Yosuke Mori, Hiroko Arao, Tadashi Tanaka, Yoshiya J Diabetes Investig Articles AIMS/INTRODUCTION: The combination therapy of dipeptidyl‐peptidase (DPP)‐4 inhibitor and α‐glucosidase inhibitors (α‐GIs) is highly effective in suppressing postprandial hyperglycemia. The aim of the present study was to compare the effects of voglibose and miglitol on glucose fluctuation, when used in combination with DPP‐4 inhibitor by using continuous glucose monitoring (CGM). MATERIALS AND METHODS: In a randomized cross‐over study, 16 patients with type 2 diabetes who presented with postprandial hyperglycemia despite alogliptin (25 mg) were treated with voglibose (0.9 mg) or miglitol (150 mg). We measured standard deviation (SD); mean amplitude of glycemic excursions (MAGE), and mean, minimum and maximum glucose measured by CGM during three phases (alogliptin monotherapy, dual therapy of alogliptin and voglibose, and dual therapy of alogliptin and miglitol). The primary outcome measure was SD between α‐GIs. RESULTS: SD was significantly improved by the addition of either voglibose (18.9 ± 10.1) or miglitol (19.6 ± 8.2) to alogliptin monotherapy (36.2 ± 8.7). MAGE improved significantly with the addition of either voglibose (57.5 ± 26.1, P < 0.01) or miglitol (64.6 ± 26.2, P < 0.01) to alogliptin monotherapy (101.5 ± 21.5). There was no significant difference in glucose fluctuation between α‐GIs. There were no differences between two groups in mean (132.6 ± 21.4 and 138.7 ± 25.4) and maximum (184.3 ± 48.7 and 191.9 ± 38.3). The minimum glucose under alogliptin plus voglibose (94.9 ± 20.2) was significantly lower than that under alogliptin and miglitol (105.3 ± 21.0). CONCLUSIONS: Glucose fluctuation was improved by the addition of voglibose or miglitol to alogliptin. Glucose fluctuations and postprandial hyperglycemia were similar between α‐GIs. This trial was registered with the University Hospital Medical Information Network (no. UMIN R000010028). Wiley-Blackwell 2013-03-07 2013-07-08 /pmc/articles/PMC4020235/ /pubmed/24843685 http://dx.doi.org/10.1111/jdi.12059 Text en Copyright © 2013 Asian Association for the Study of Diabetes and Wiley Publishing Asia Pty Ltd |
spellingShingle | Articles Kurozumi, Akira Okada, Yosuke Mori, Hiroko Arao, Tadashi Tanaka, Yoshiya Efficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring |
title | Efficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring |
title_full | Efficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring |
title_fullStr | Efficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring |
title_full_unstemmed | Efficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring |
title_short | Efficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring |
title_sort | efficacy of α‐glucosidase inhibitors combined with dipeptidyl‐peptidase‐4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020235/ https://www.ncbi.nlm.nih.gov/pubmed/24843685 http://dx.doi.org/10.1111/jdi.12059 |
work_keys_str_mv | AT kurozumiakira efficacyofaglucosidaseinhibitorscombinedwithdipeptidylpeptidase4inhibitoralogliptinforglucosefluctuationinpatientswithtype2diabetesmellitusbycontinuousglucosemonitoring AT okadayosuke efficacyofaglucosidaseinhibitorscombinedwithdipeptidylpeptidase4inhibitoralogliptinforglucosefluctuationinpatientswithtype2diabetesmellitusbycontinuousglucosemonitoring AT morihiroko efficacyofaglucosidaseinhibitorscombinedwithdipeptidylpeptidase4inhibitoralogliptinforglucosefluctuationinpatientswithtype2diabetesmellitusbycontinuousglucosemonitoring AT araotadashi efficacyofaglucosidaseinhibitorscombinedwithdipeptidylpeptidase4inhibitoralogliptinforglucosefluctuationinpatientswithtype2diabetesmellitusbycontinuousglucosemonitoring AT tanakayoshiya efficacyofaglucosidaseinhibitorscombinedwithdipeptidylpeptidase4inhibitoralogliptinforglucosefluctuationinpatientswithtype2diabetesmellitusbycontinuousglucosemonitoring |